Phase 3 trial of leniolisib in activated PI3Kδ syndrome, dabrafenib plus trametinib in relapsed/refractory hairy cell leukemia, and TγδLGL leukemia as a more symptomatic subset of leukemia

Lineage switching in MLL/AF4 leukemia, ibrutinib in mantle cell lymphoma with CNS relapse, and gilteritinib plus azacitidine in newly diagnosed FLT3-mutated AML: In this week’s episode we’ll discuss the role of epigenetic regulator genes in lineage switching in MLL/AF4 leukemia, learn more about the efficacy of ibrutinib in mantle cell lymphoma with central nervous system relapse, and discuss the findings from a p by Blood Podcast

23 min listen

Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibodies armed with B-BiTEs by Blood Podcast

25 min listen

Microbiome and CD4 T-cell recovery after allogeneic HCT, and a paradigm shift to CAR T-cells in the second line for large B-cell lymphoma?: In this week’s episode we’ll discuss the effects of intestinal microbial diversity on patient outcomes following allogeneic hematopoietic cell transplant and review the results of three different phase 3 trials comparing CAR T-cells to autologous stem cel by Blood Podcast

20 min listen

Tolerability of CD19 CAR T cells in lymphoma, causes of platelet spherocytosis, and using prebiotics to reduce GVHD: In this week’s episode, we’ll discuss patient-reported outcomes in the phase 3 ZUMA-7 trial of CAR T-cell therapy in second-line relapsed/refractory large B-cell lymphoma, learn more about the association between the loss of α4A- and β1-tubulin and severe by Blood Podcast

20 min listen

$Tolerability of CD19 CAR T cells in lymphoma, causes of platelet spherocytosis, and using prebiotics to reduce GVHD: In this week’s episode, we’ll discuss patient-reported outcomes in the phase 3 ZUMA-7 trial of CAR T-cell therapy in second-line relapsed/refractory large B-cell lymphoma, learn more about the association between the loss of α4A- and β1-tubulin and severe$

Season 2, Episode 7: In this week’s episode, we will learn about the cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura, review outcomes of a phase 2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease, by Blood Podcast

17 min listen

Effects of iron repletion on donor RBC quality, long-term outcomes in relapsed/refractory hairy cell leukemia after vemurafenib, and off-the-shelf cryopreserved platelets for detecting HIT: In this week’s episode, we’ll discuss the effects of iron repletion on the quality of donated red blood cells and donor well-being, learn more about the long-term outcomes of patients with relapsed/refractory hairy cell leukemia after vemurafenib monother by Blood Podcast

21 min listen

$Effects of iron repletion on donor RBC quality, long-term outcomes in relapsed/refractory hairy cell leukemia after vemurafenib, and off-the-shelf cryopreserved platelets for detecting HIT: In this week’s episode, we’ll discuss the effects of iron repletion on the quality of donated red blood cells and donor well-being, learn more about the long-term outcomes of patients with relapsed/refractory hairy cell leukemia after vemurafenib monother$

Asciminib versus bosutinib in CML; dopamine signaling and hematopoietic stem cells; complement factor C5 and VTE risk: In this week’s episode, we’ll learn more about the efficacy of asciminib in patients with chronic myeloid leukemia who are resistant or intolerant to two or more tyrosine kinase inhibitors, discuss the role of dopamine signaling in hematopoietic stem and by Blood Podcast

21 min listen

Cell therapy options for chemo-sensitive DLBCL, PIGA mutations in a novel subtype of hemochromatosis, and triplet combination therapy in high-risk CLL: In this week's podcast, we’ll compare the efficacy of autologous stem cell transplant to CAR T-cell therapy for relapsed diffuse large B-cell lymphoma, learn more about a novel subtype of hemochromatosis caused by constitutional PIGA mutations, and discus by Blood Podcast

21 min listen

Season 2, Episode 19: In this week’s episode, we will review a randomized phase 3 study of patients with high-risk peripheral T-cell lymphoma that compares results from autologous versus allogeneic stem cell transplant during consolidation, look at a report that examines the s by Blood Podcast

19 min listen

Structural racism and AML survival, promoter competition and hemoglobin switching, and CAR T-cell therapy and high-risk cytogenetics in ALL: In this week’s episode we’ll first cover a research article demonstrating the striking contribution of neighborhood disadvantage to racial and ethnic disparities in survival in patients with acute myeloid leukemia. The second research article provides a m by Blood Podcast

18 min listen

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML; inhibition of PLK4 in TP53-mutated AML; the role of CD44 in Plasmodium falciparum infection by Blood Podcast

23 min listen

Sustained MRD negativity & outcomes in myeloma, therapeutic targeting of VWF in TTP, and improving CAR T-cells in CLL with PI3 kinase inhibition: On this week’s podcast, we’ll review a recent analysis of phase 3 daratumumab studies looking at the prognostic impact of sustained minimal residual disease, or MRD negativity in patients with multiple myeloma. Next, we’ll hear more about a novel thrombol by Blood Podcast

20 min listen

Season 2, Episode 22: In this week’s episode, we will review a study in sickle cell disease patients reporting abnormal retention of mitochondria in circulating red cells and elevated mitochondrial DNA in plasma, learn more about the fate of FLT3-ITD clones in AML patients tre by Blood Podcast

18 min listen

GDF3 simultaneously antagonizes BMP signaling and activates TGFβ receptor signaling by PaperPlayer biorxiv cell biology

20 min listen

Rivaroxaban after cancer surgery, genetics and survival in severe aplastic anemia, and a 5-year follow up of rituximab-venetoclax in relapsed/refractory CLL: In this week’s episode discuss the efficacy of rivaroxaban as antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer, learn more about the association between genomic variants and survival outcomes after hematopoietic cell transplanta by Blood Podcast

20 min listen

$Rivaroxaban after cancer surgery, genetics and survival in severe aplastic anemia, and a 5-year follow up of rituximab-venetoclax in relapsed/refractory CLL: In this week’s episode discuss the efficacy of rivaroxaban as antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer, learn more about the association between genomic variants and survival outcomes after hematopoietic cell transplanta$

Optimizing CAR T-cell therapies in lymphoma: Improving response, fighting cytokine release syndrome, and identifying mechanisms of resistance: Studies have shown that chimeric antigen receptor (CAR) T-cell therapies produce responses in patients with relapsed/refractory B-cell lymphomas, but researchers continue to look for ways to improve efficacy, decrease toxicity, and overcome treatment... by Blood & Cancer

26 min listen

$Optimizing CAR T-cell therapies in lymphoma: Improving response, fighting cytokine release syndrome, and identifying mechanisms of resistance: Studies have shown that chimeric antigen receptor (CAR) T-cell therapies produce responses in patients with relapsed/refractory B-cell lymphomas, but researchers continue to look for ways to improve efficacy, decrease toxicity, and overcome treatment...$

Spotlight on Immunotherapy at ASCO22: Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh’s Hillman Cancer Center, highlight key advances in early phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting and also address toxicities,... by ASCO Daily News

27 min listen

Obinutuzumab, ibrutinib, and venetoclax in untreated CLL with deletion(17p)/TP53 mutation; NOTCH2 mutants promote chemo-resistance in DLBCL; and the role of DBY/HLA class II complexes in chronic GVHD by Blood Podcast

22 min listen

Episode 12: Tinder for T Cells - Bispecifics in DLBCL by WolverHeme Happy Hour

58 min listen

Season 1, Episode 26: In this week’s episode we’ll examine the cause and clinical significance of dysplastic hematopoiesis at time of diagnosis in patients with multiple myeloma, review a multi‐omics analysis of patients that have undergone blastic transformation of chronic my by Blood Podcast

17 min listen

Season 1, Episode 42: In this week’s episode, we will review a study that utilized whole-genome sequencing to define the mutational spectrum and clonal architecture of myelodysplastic/ myeloproliferative neoplasms, learn more about the association between plasma levels of grow by Blood Podcast

16 min listen

Mark J. Levis, MD, PhD - Finding the Key to Better Outcomes in FLT3-Mutated AML: Guidance on New Evidence With Next-Gen FLT3 Inhibitors: Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast

31 min listen

Season 2, Episode 1: In this week’s episode, we will review a study that shows that non-invasive imaging of T cell metabolic activity can detect early graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, learn more about how detailed assessment by Blood Podcast

17 min listen

Brentuximab plus nivolumab in refractory/relapsed Hodgkin lymphoma, the signature of aging hematopoietic stem cells, and hepatocyte neogenin in iron homeostasis: In this week's episode, we’ll discuss the safety and efficacy of brentuximab vedotin in combination with nivolumab in patients with relapsed and refractory classical Hodgkin lymphoma, learn more about the aging signature of murine hematopoietic stem cells by Blood Podcast

16 min listen

$Brentuximab plus nivolumab in refractory/relapsed Hodgkin lymphoma, the signature of aging hematopoietic stem cells, and hepatocyte neogenin in iron homeostasis: In this week's episode, we’ll discuss the safety and efficacy of brentuximab vedotin in combination with nivolumab in patients with relapsed and refractory classical Hodgkin lymphoma, learn more about the aging signature of murine hematopoietic stem cells$

Season 1, Episode 43: In this week’s episode, we will learn more about the immune defects and granule dysfunction in the leukocytes of patients with the rare recessive platelet disorder, gray platelet syndrome, review a study that examines the cost effectiveness of first-line by Blood Podcast

20 min listen

Season 1, Episode 17: This week’s episode will highlight the development of a factor VIII replacement therapy for patients with severe Hemophilia A, examine a novel pathway of resistance of FLT3-ITD+ AML cells to FLIT3 inhibitors, and review long-term results of a pilot study by Blood Podcast

18 min listen

Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss by Blood Podcast

23 min listen

Season 1, Episode 29: In this episode we’ll review the risk of bleeding after initiating treatment for acquired hemophilia A, examine the functional effect of antibodies leading to immune TTP and how this can be used as a biomarker, and finally, a blast from the past – we will by Blood Podcast

17 min listen

Germline predisposition variants occur in all age groups in MDS, αβ-haplo-HCT excels in children with acute leukemias/MDS, and poor outcomes after CAR T cell failure in B-cell lymphomas: In this week’s episode, research shows that in patients with myelodysplastic syndromes, or MDS, the frequency of pathogenic or likely pathogenic germline variants is relatively high across all age groups, not just younger patients. Based on these results, by Blood Podcast

20 min listen

Immune thrombocytopenia in pregnancy, ASCT in adults with inborn errors of immunity, and long-term health outcomes of childhood AML survivors: In this week’s episode we’ll discuss whether pregnancy increases the risk of bleeding in women with immune thrombocytopenia, compare the outcomes of allogeneic stem cell transplantation versus conservative management in adults with inborn errors of immuni by Blood Podcast

19 min listen